https://www.selleckchem.com/products/Eloxatin.html
The observed 3- and 5-year EFS was 87.4% (CI 72.4-100%) and 87.4% (CI 72.4-100%), progression free survival (PFS) was 92.9% (CI 80.3-100%) and 92.9% (CI 80.3-100%), overall survival was 94.1% (CI 83.6-10 and 80.7% (CI 58.3-10, respectively. Comparison to the historical control showed statistically significant better PFS for mifamurtide patients (Landmark analysis; p=0.044). Risk of progression was 5-times lower for the mifamurtide group (Cox model; HR 0.21, p=0.136). Only subtle differences in lymphocyte counts were observed across
Like
Comment
Share
